Barclays
COGT icon

Barclays’s Cogent Biosciences COGT Stock Holding History

Barclays’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-79,000
Closed -$567K – 5520
2025
Q2 		$567K Buy
+79,000
New +$438K ﹤0.01% 3693

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Barclays's COGT Position: Q1 2026 in Review

Barclays reduced its Cogent Biosciences (COGT) stake by 90% in Q1 2026, selling an estimated $10.7M and leaving 31,261 shares worth $1.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2639.

Barclays first reported a position in COGT in Q2 2018 and has held it in 24 quarters since. The position peaked at $11.4M in Q4 2025. 305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

  • Barclays held 31,261 shares of Cogent Biosciences worth $1.2M as of Q1 2026.
  • Barclays sold 290,345 Cogent Biosciences shares in Q1 2026, an estimated $10.7M.
  • Cogent Biosciences made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2639 holding.
  • Barclays first reported a position in Cogent Biosciences in Q2 2018 and has held it in 24 quarters since.
  • Barclays's Cogent Biosciences position peaked at $11.4M in Q4 2025.
  • 305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.